Jaguar Health (JAGX) Net Income towards Common Stockholders (2014 - 2026)
Jaguar Health (JAGX) reported Net Income towards Common Stockholders of -$7.0 million for Q1 2026, up 32.96% year-over-year from -$5.3 million in Q1 2025, and up 69.75% quarter-over-quarter from -$23.2 million in Q4 2025.
Jaguar Health (JAGX) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$7.0 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$7.0 million, up 32.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$50.4 million (down 25.38% YoY), and the FY2025 annual result was -$53.6 million, down 39.18% from the prior year.
- Net Income towards Common Stockholders advanced to -$7.0 million in Q1 2026 per JAGX's latest filing, from -$23.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$7.0 million in Q1 2026 and troughed at -$23.2 million in Q4 2025.
- A 5-year average of -$11.1 million and a median of -$10.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders jumped 47.03% in 2022, then slumped 126.63% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$7.6 million in 2022, then fell by 20.96% to -$9.2 million in 2023, then slipped by 11.6% to -$10.2 million in 2024, then tumbled by 126.63% to -$23.2 million in 2025, then surged by 69.75% to -$7.0 million in 2026.
- Business Quant data shows JAGX's Net Income towards Common Stockholders at -$7.0 million in Q1 2026, -$23.2 million in Q4 2025, and -$9.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | -7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.02 Mn |
| Dec 31, 2025 | -23.19 Mn |
| Sep 30, 2025 | -9.65 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -10.46 Mn |
| Dec 31, 2024 | -10.23 Mn |
| Sep 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -9.49 Mn |
| Mar 31, 2024 | -9.23 Mn |
| Dec 31, 2023 | -9.17 Mn |
| Sep 30, 2023 | -7.78 Mn |
| Jun 30, 2023 | -12.15 Mn |
| Mar 31, 2023 | -12.20 Mn |
| Dec 31, 2022 | -7.58 Mn |
| Sep 30, 2022 | -12.52 Mn |
| Jun 30, 2022 | -9.37 Mn |
| Mar 31, 2022 | -17.99 Mn |
| Dec 31, 2021 | -14.31 Mn |
| Sep 30, 2021 | -12.19 Mn |
| Jun 30, 2021 | -14.08 Mn |